List of Excipients in Branded Drug WAL-FEX

« Back to Dashboard

Generic Drugs Containing WAL-FEX

Company	Ingredient	NDC	Excipient
Walgreens Company	fexofenadine hydrochloride	0363-0784	CROSCARMELLOSE SODIUM
Walgreens Company	fexofenadine hydrochloride	0363-0784	FD&C RED NO. 40
Walgreens Company	fexofenadine hydrochloride	0363-0784	FERROSOFERRIC OXIDE
Walgreens Company	fexofenadine hydrochloride	0363-0784	HYPROMELLOSE 2910

What are the Most Frequently-Used Excipients in WAL-FEX?

# Of NDCs	Excipient
1	CROSCARMELLOSE SODIUM
1	FD&C RED NO. 40
1	FERROSOFERRIC OXIDE
1	HYPROMELLOSE 2910

WAL-FEX Excipient Strategy and Commercial Opportunities for Fexofenadine

Last updated: September 24, 2026

WAL-FEX is a Walgreens private-label fexofenadine hydrochloride product positioned in the U.S. OTC antihistamine market. Its commercial value comes from low-cost, high-volume substitution for branded Allegra and other generic fexofenadine products. The strongest excipient opportunities are formulation differentiation, pediatric and liquid presentations, swallowability, dose flexibility, packaging efficiency, and retailer-specific value positioning.

Because fexofenadine is an established OTC active ingredient, excipients are unlikely to create meaningful composition-of-matter exclusivity. Their value is commercial and operational: improving patient use, reducing manufacturing cost, supporting differentiated dosage forms, and creating private-label shelf segmentation.

What is WAL-FEX and how is fexofenadine regulated?

WAL-FEX is generally marketed as a Walgreens store-brand allergy product containing fexofenadine hydrochloride. The primary U.S. dosage strengths associated with the fexofenadine OTC market are 30 mg, 60 mg, and 180 mg oral products.

Attribute	WAL-FEX commercial profile
Active ingredient	Fexofenadine hydrochloride
Therapeutic class	Second-generation H1 antihistamine
Primary use	Relief of seasonal allergic rhinitis symptoms and chronic urticaria symptoms
U.S. status	OTC drug product
Main reference brand	Allegra
Typical adult dosing	60 mg twice daily or 180 mg once daily
Common dosage forms	Immediate-release tablets, orally disintegrating tablets, oral suspension
Primary channel	Walgreens retail, e-commerce, and private-label distribution
Core commercial advantage	Lower retail price than branded fexofenadine

Fexofenadine is regulated under the FDA OTC framework rather than through an active branded prescription NDA strategy. Labeling must comply with applicable FDA OTC requirements, including the active ingredient, permitted claims, directions, warnings, and standardized Drug Facts presentation.[1]

What excipients are important in WAL-FEX tablets?

The excipient system for an immediate-release fexofenadine tablet normally prioritizes manufacturability, rapid disintegration, low tablet weight, chemical stability, and acceptable mouthfeel.

Typical functional excipient categories include:

Excipient category	Typical function	Strategic relevance
Diluent	Provides tablet mass and compressibility	Determines cost, tablet size, and swallowability
Binder	Improves granule or tablet strength	Controls friability and production yield
Disintegrant	Promotes tablet breakup after administration	Supports rapid release
Glidant	Improves powder flow	Reduces weight variation and hopper issues
Lubricant	Prevents sticking and ejection defects	Necessary for high-speed compression
Film former	Protects tablet surface and improves appearance	Enables color and branding
Opacifier or colorant	Controls visual identity	Supports product differentiation
Sweetener or flavor	Improves orally disintegrating or liquid products	Important for pediatric and geriatric use

A conventional fexofenadine tablet can use microcrystalline cellulose, starch-based excipients, croscarmellose sodium or sodium starch glycolate, colloidal silicon dioxide, magnesium stearate, povidone, and a film-coating system. The specific composition of a WAL-FEX SKU must be verified against its current package insert or product label before making a regulatory, sourcing, or patent determination.

How should the tablet platform be optimized?

The base tablet should use a low-cost direct-compression or dry-granulation process where feasible. Fexofenadine products compete primarily on retail price, so the formulation should avoid unnecessary wet processing, excessive coating weight, or specialized excipients that do not improve consumer performance.

The preferred design objectives are:

1. Rapid disintegration without excessive friability.
2. Small tablet dimensions at the 60 mg and 180 mg strengths.
3. Low sensitivity to lubricant overmixing.
4. Stable appearance under high humidity.
5. Reliable content uniformity at lower strengths.
6. Compatibility with high-speed blister or bottle packaging.
7. Minimal dependence on single-source specialty excipients.

A formulation using standard compendial excipients can reduce supply-chain risk and support contract manufacturing across multiple sites. The main technical risk is balancing tablet hardness against rapid disintegration, particularly where high compression force is used to produce a smaller 180 mg tablet.

What formulation opportunities exist for WAL-FEX?

Orally disintegrating tablets

An orally disintegrating fexofenadine product could target consumers who have difficulty swallowing conventional tablets. The formulation would require a porous matrix, rapid-wetting disintegrant, taste-masking system, and moisture-resistant packaging.

Potential excipient technologies include:

• Mannitol for cooling mouthfeel and compactibility.
• Crospovidone or croscarmellose sodium for rapid disintegration.
• Fine-particle cellulose or spray-dried mannitol for mouthfeel.
• Flavor and sweetener systems for bitterness control.
• Polymer or lipid-based taste-masking coatings.
• Desiccant-containing bottles or high-barrier unit-dose blisters.

The commercial opportunity is stronger in 30 mg or 60 mg products than in 180 mg products because lower-dose units can be made smaller and easier to disperse. An ODT could also create a premium store-brand tier without changing the active ingredient.

Oral suspension

A fexofenadine oral suspension could address children and adults who cannot swallow tablets. The principal excipient challenges are sedimentation, redispersibility, viscosity, preservative performance, taste, and dosing accuracy.

A commercial suspension platform would likely require:

• Suspending agents such as microcrystalline cellulose and carboxymethylcellulose systems.
• Wetting agents to prevent hydrophobic particle flotation.
• Sweeteners and flavors for palatability.
• Buffering agents to control pH.
• Preservative systems compatible with the final pH and container.
• A calibrated oral syringe rather than a household spoon.
• A child-resistant closure and dosing adapter.

The product would need to compete with existing liquid antihistamines, including cetirizine and loratadine. Fexofenadine's non-sedating positioning could support a premium pediatric allergy product, but palatability and stability would determine repeat purchase.

Chewable tablets

Chewables could extend WAL-FEX into family and pediatric allergy products. The main technical barrier is the bitter or medicinal taste of the active ingredient. Direct compression alone is unlikely to deliver sufficient taste masking.

Potential solutions include:

• Polymer-coated drug particles.
• Ion-exchange resin complexes.
• Lipid-based taste masking.
• Multi-particulate granules embedded in a chewable matrix.
• High-intensity sweetener blends with fruit flavors.

Chewables increase formulation complexity and may have higher tooling, stability, and quality-control costs. They are most attractive when positioned as a family product rather than a direct substitute for the lowest-priced tablet.

What commercial opportunities exist for WAL-FEX?

How can excipients support private-label price tiers?

Walgreens can use the same active ingredient across multiple tiers:

Tier	Dosage form	Excipient strategy	Commercial role
Value	Standard tablet	Conventional compendial excipients	Lowest retail price
Core	Film-coated tablet	Improved swallowability and appearance	Main volume SKU
Premium	ODT or fast-dissolve tablet	Taste masking and rapid disintegration	Higher margin
Family	Chewable or liquid	Sweetener, flavor, suspension system	Pediatric and household use
Convenience	Unit-dose blister	High-barrier packaging and portability	Travel and adherence

This architecture allows retailer segmentation without changing the active ingredient or therapeutic claim.

Can packaging create more value than reformulation?

Yes. For an established OTC antihistamine, packaging can deliver a faster commercial return than a new dosage form. Relevant opportunities include:

• Single-dose travel blisters.
• 30-, 60-, 90-, and 180-count bottles.
• Calendar blister packs for once-daily 180 mg dosing.
• Senior-friendly easy-open closures where permitted.
• Child-resistant packaging with clearer adult instructions.
• Combination allergy-season multipacks.
• E-commerce-compatible bottles with reduced breakage and lower dimensional weight.

Packaging changes can also reduce moisture exposure and stabilize ODT or chewable products without introducing a new excipient system.

What FDA and Orange Book status applies to WAL-FEX?

WAL-FEX is generally an OTC monograph product, not an FDA-approved prescription NDA product. It therefore should not be treated like an Orange Book-listed branded prescription medicine.

Regulatory issue	WAL-FEX implication
FDA pathway	OTC monograph compliance
Orange Book listing	Not normally expected for a monograph OTC product
Paragraph IV certification	Generally not applicable to the monograph product itself
Prescription exclusivity	Not applicable
OTC labeling	Must comply with applicable FDA requirements
New dosage form	May require a separate regulatory assessment
New active ingredient	Not relevant to standard fexofenadine products

A reformulated product that falls outside the applicable OTC monograph conditions could require an FDA submission or another regulatory pathway. A new route of administration, materially different dosage form, novel combination, or unsupported claim can change the regulatory analysis.[1,2]

What patents protect fexofenadine and WAL-FEX?

The original fexofenadine composition and major branded-product rights are expired or no longer provide a practical barrier to routine generic and private-label tablet entry. WAL-FEX is not generally associated with a meaningful product-specific patent estate.

Patent category	Current commercial significance
Fexofenadine active ingredient	Historical protection; expired
Standard immediate-release tablets	Low barrier; multiple generic suppliers
Routine excipient combinations	Usually weak patent position
ODT formulation	Potentially protectable if technically differentiated
Taste-masked particles	Potential formulation patent opportunity
Sustained-release delivery	Potentially protectable, but limited relevance to standard WAL-FEX
Packaging configuration	Possible design or utility protection, usually narrow
Method-of-use claims	Limited value for ordinary OTC allergy indications
Manufacturing process	Potential trade-secret value

A new excipient system could support patent claims only if it provides a specific technical effect, such as improved stability, taste masking, dissolution, bioavailability, or manufacturability. Simply replacing one conventional filler or disintegrant with another would rarely create a durable competitive moat.

When does fexofenadine lose exclusivity?

Fexofenadine has already lost practical market exclusivity in the United States. Generic and store-brand products compete with Allegra across tablets, capsules, and liquid presentations.

The relevant commercial question is therefore not loss of exclusivity. It is whether a new formulation can achieve one or more of the following:

• Higher gross margin.
• Better retailer differentiation.
• Improved pediatric adherence.
• Lower manufacturing cost.
• Better supply reliability.
• Stronger e-commerce conversion.
• Greater seasonal basket size.
• Lower returns from damaged or poorly tolerated products.

Which companies compete with WAL-FEX?

WAL-FEX competes with branded Allegra, generic fexofenadine products, and alternative second-generation antihistamines.

Competitor group	Examples	Competitive basis
Branded fexofenadine	Allegra	Brand recognition and broad product range
Retail private labels	CVS, Amazon Basic Care, store brands	Price and availability
Generic manufacturers	Multiple FDA-compliant suppliers	Lowest unit cost
Other antihistamines	Claritin, Zyrtec, generic loratadine, cetirizine	Substitution and consumer habit
Combination products	Fexofenadine/pseudoephedrine products	Congestion positioning

The most direct competitive pressure comes from generic fexofenadine and other retailer brands. Cetirizine may compete aggressively on price, while loratadine often competes through brand familiarity and broad OTC distribution.

What manufacturing and IP barriers affect commercial expansion?

The standard tablet has low manufacturing barriers. The more defensible opportunities arise in technically demanding dosage forms.

Low-barrier products

• Conventional immediate-release tablets.
• Film-coated tablets.
• Standard bottles.
• Conventional blister packs.

Moderate-barrier products

• Low-dose content-uniformity formulations.
• Moisture-sensitive ODTs.
• Pediatric suspensions.
• Taste-masked chewables.

Higher-barrier opportunities

• Multiparticulate taste-masked systems.
• Long-acting formulations.
• Abuse-resistant or tamper-evident delivery systems.
• Novel combination products.
• Proprietary high-barrier packaging with demonstrated stability benefits.

Trade secrets may be more valuable than patents for granulation parameters, coating conditions, taste-masking processes, suspension homogenization, and packaging line settings. Patent protection is most credible where the formulation produces measurable performance advantages that are difficult to design around.

How strong is the WAL-FEX patent estate?

The estate is weak for standard fexofenadine tablets and stronger only where a differentiated formulation is developed.

Factor	Assessment
Active ingredient protection	Weak or expired
Standard tablet protection	Weak
OTC market access	Broad
Generic substitution risk	High
Formulation differentiation potential	Moderate
ODT or taste-masking opportunity	Moderate to strong
Manufacturing trade-secret value	Moderate
Litigation exposure	Low for conventional products
Regulatory execution risk	Moderate for new dosage forms

What generic launch scenarios exist?

A standard WAL-FEX tablet faces immediate competitive entry from qualified suppliers because the product uses an established OTC active ingredient and conventional dosage form.

Three launch scenarios are commercially relevant:

1. A lowest-cost standard tablet competes primarily on procurement and retail price.
2. A differentiated ODT, chewable, or liquid product commands a higher margin but requires more development and quality control.
3. A retailer-exclusive formulation or pack size limits direct price comparison and improves shelf differentiation.

The lowest-risk program is a conventional tablet supported by dual-source API and excipient supply. The highest-value program is a pediatric or fast-dissolve platform with demonstrated taste and usability benefits.

Key Takeaways

• WAL-FEX is a Walgreens private-label fexofenadine product competing in a mature OTC market.
• Standard tablet excipients should prioritize low cost, rapid disintegration, content uniformity, and high-speed manufacturability.
• Conventional fexofenadine tablets have limited patent protection and high generic-entry risk.
• The strongest commercial opportunities are ODTs, taste-masked chewables, pediatric suspensions, and differentiated packaging.
• Excipients are more valuable for margin improvement and consumer usability than for exclusivity.
• A multitiers strategy can support value, core, premium, and family WAL-FEX SKUs.
• Formulation patents are credible only where the excipient system produces a measurable technical benefit.
• Manufacturing know-how and supply-chain control may provide more practical protection than patents.
• Standard tablets have low regulatory and manufacturing barriers; pediatric liquids and taste-masked products carry higher execution risk.
• Orange Book and Paragraph IV strategies generally do not apply to a conventional OTC monograph WAL-FEX product.

FAQs About WAL-FEX Excipient Strategy

Can WAL-FEX use the same excipients as generic Allegra?

Yes. Conventional compendial excipients can be used if the finished product meets applicable quality, stability, labeling, and manufacturing requirements. Exact composition should not be copied where a third-party formulation patent or proprietary technology applies.

Is fexofenadine suitable for an orally disintegrating tablet?

Yes. Fexofenadine can be developed as an ODT, but taste masking, moisture control, mechanical strength, and rapid disintegration require specialized formulation development.

What is the best pediatric opportunity for WAL-FEX?

A palatable, preservative-appropriate oral suspension or taste-masked chewable is the strongest pediatric opportunity. The product must provide accurate dosing and clear age-based instructions.

Do excipients create patent protection for WAL-FEX?

They can, but only when the formulation has a novel combination and a demonstrated technical effect. Routine substitutions among fillers, binders, lubricants, and disintegrants generally provide limited patent strength.

Does WAL-FEX face biosimilar competition?

No. Fexofenadine is a small-molecule antihistamine, not a biologic. The relevant competitors are generic drugs, private-label products, branded Allegra, and alternative antihistamines.

References

1. U.S. Food and Drug Administration. (2023). Over-the-counter monograph drug products. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs/otc-monograph-drug-products

2. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-D/part-341

3. U.S. Food and Drug Administration. (2024). DailyMed: Fexofenadine hydrochloride drug labels. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/

4. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.

5. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/ index.cfm